Tavilermide (MIM-D3) (Synonyms: MIM-D3) |
رقم الكتالوجGC31676 |
Tavilermide (MIM-D3) هو ناهض انتقائي جزئي لـ TrkA ، أو محاكى عامل نمو الأعصاب (NGF).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 263251-78-1
Sample solution is provided at 25 µL, 10mM.
Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1].
[1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85.
Average Rating: 5
(Based on Reviews and 37 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *